[Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review].
OBJECTIVE
Systematic review on efficacy and safety of intravitreal bevacizumab (IVB) in the treatment of neovascular glaucoma (NVG). All original papers published in Medline (prior to August 2008) were included.


METHODS
Search and selection of information on the internet and in Medline, validated by Kappa Index (K). Statistical and clinical study of the results in the selected articles on a one by one basis.


RESULTS
26 original papers analyzed the efficacy and safety of the procedure in case reports and short series of cases (127 eyes). The efficacy calculated in the sample was 68.7% and the recurrence rate was 18.6% in 4.2 months of follow-up. All studies were after 2006 and none of them was a clinical randomized controlled assay. Ophthalmic complications were under 0.78% and no systemic complications were found.


CONCLUSIONS
The use of bevacizumab demonstrates that intravitreal injections may be effective and useful to manipulate growth factors in the anterior chamber. IVB could serve as a first line treatment for NVG. Clinical trials are needed to confirm these results before its use is authorized.
Unidad de Investigación Ocular y Láser, Centro de Oftalmología Bonafonte, Barcelona, Departamento de Investigación Láser, IMC-Investiláser, Sabadell, Barcelona, España. pmc@investilaser.com
P A
PA
Martínez-Carpio
E
E
Bonafonte-Márquez
C D
CD
Heredia-García
S
S
Bonafonte-Royo
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015355:Glaucoma, Neovascular / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
Eficacia y seguridad de la inyección intravítrea de bevacizumab en el tratamiento del glaucoma neovascular: revisión sistemática.